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Summary Between July 1979 and December 1981, 43 patients with metastatic germ-cell tumours (36
testicular non-seminomas and 7 testicular seminomas) were treated with 2-6 cycles of bleomycin, etoposide
and cis-platin (BEP). Forty (93%) are alive, 37 (86%) with no evidence of disease. Of 36 men with testicular
non-seminoma 30 (83.3%) are alive and disease-free at 8-38 months (median 17.0 months). In the latter
group 25/28 (89.3%) who had had no prior irradiation are alive and disease-free. Fourteen non-seminoma
patients had small volume metastases and 13 are in complete remission, as are 12/14 patients with bulky
disease. All 7 patients with advanced seminoma are alive and disease-free. It is concluded that BEP is a well
tolerated and effective first line treatment for patients with metastatic germ-cell tumours.
Before the development, during the past decade, of
effective chemotherapy for malignant germ-cell
tumours, the majority of patients with advanced
disease died and their survival time was short. In
contrast, many patients in this previously hopeless
category are now curable, although two major
problems remain, the toxicity of therapy and the
poor prognosis of patients with bulky disseminated
disease. Approximately 70% of patients with
advanced non-seminomatous germ-cell testicular
tumours are rendered disease-free with cis-platin,
vinblastine and bleomycin (PVB) (Einhorn &
Donohue, 1977; 1979; Einhorn & Williams, 1980).
However, the outcome of treatment is influenced by
the size of metastases so that, whereas patients with
small volume disease have an excellent prognosis,
the association of bulky abdominal and thoracic
tumour significantly reduces the chance of cure.
Furthermore, PVB is associated with considerable
morbidity, particularly myelosuppression, and a
small percentage of patients die from
chemotherapy-related complications. Although
toxicity may not be a primary concern in high risk
patients with bulky metastases, it is important in
patients with good prognosis where better-tolerated
combinations may be developed without loss of
therapeutic effectiveness. Patients who have been
irradiated tolerate PVB poorly and the risk of
severe bone marrow depression is high (Einhorn &
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Williams, 1980). Furthermore, our own experience
suggested that the use of vinblastine was associated
with a risk of gastro-intestinal damage in previously
irradiated patients. For these reasons, in 1979,
vinblastine in the PVB combination was replaced
by etoposide (VP-16-213) a semi-synthetic derivative
of podophyllotoxin which has shown activity as a
single agent in testicular non-seminoma patients
relapsing after first line chemotherapy (Table I)
(Cavalli et al., 1981; Fitzharris et al., 1980;
Newlands & Bagshawe, 1977; Williams et al., 1980,
1982; Varini & Cavalli, 1982; Bremer et al., 1982).
Initially, the combination of bleomycin, etoposide
and cis-platin (BEP) was used only in patients
relapsing after radiotherapy but encouraged by
preliminary experience, BEP was introduced as first
line treatment for patients with Stage II, III & IV
disease in 1980.
This report describes the results obtained with
BEP in the management of 43 patients with
metastatic germ-cell tumours, 36 of whom had non-
seminomatous testicular tumours and 7 advanced
testicular seminoma.
Table I Response to etoposide of testicular non-semi-
noma patients relapsing after first line chemotherapy
Authors No. ofpatients Response
Fitzharris et al., 1980 24 11
Williams & Einhorn, 1982 5 3
Varini & Cavalli, 1982 30 6
Bremer et al., 1982 23 5
Total 82 25 (30.5%)
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Patients and methods
Patients
Patients who had received prior chemotherapy were
excluded from the study. Between July 1979 and
December 1981, 43 patients were entered, 9 (1
seminoma and 8 testicular non-seminoma) had had
prior radiotherapy followed by relapse and 34 were
previously untreated. Details of the series are
summarised in Table TI. Non-seminoma patients
have been followed 8-38 months (median 17
months) after the start of chemotherapy and the
seminoma patients 9-22 months (median 15).
Staging
Staging included lymphography, CT scanning of
lungs and abdomen, ultrasonic scanning of liver and
retro-peritoneum, intravenous urography,
measurement of renal clearance, liver function tests
and measurement of serum a foeto protein (axFP)
and # human chorionic gonadotrophin levels
(#HCG).
Staging classification
The Royal Marsden Hospital staging classification
(Peckham, 1981a) was employed:
Table II Bleomycin, etoposide and
Stage I No metastases evident outside testis
Stage IM No clinical evidence of metastases but
persistent elevation of serum axFP
and/or JHCG levels after orchidectomy
Stage II Infra-diaphragmatic nodal metastases
IIA Metastases <2cm diam.
IIB Metastases 2-5 cm diam.
IIC Metastases >5 cm diam.
Stage III Supra-diaphragmatic nodal metastases
Abdominal status 0 =negative lymphogram, A, B,
C, as for Stage TI
Stage IV Extranodal metastases
IVL1 Pulmonary metastases, <3 in number
IVL2 Multiple small pulmonary metastases
<2 cm diam.
IVL3 Multiple pulmonary metastases.
One or more >2 cm diam.
IVH+Hepatic involvement
Abdominal status as for Stage TI.
Small volume disease. This category includes
patients in the present series with Stage IM, IIA,
IIB, IIIA and IVAL2.
Large volume disease includes Stage IIC, IIIC,
IVCL1 and IVCL3 patients.
cis-platin for metastatic testicular non-seminoma: stage distribution and results
(The Royal Marsden Hospital 1979-1981)
Time since start Time since
ofchemotherapy start of
No. of (months); disease- treatment
Stage patients NED free patients A+D (months) DID T DT T
(A) Testicular non-seminoma
IM 3 3 13,15,17
IIA 3 2 11,20 1 9
IIB 6 6 10,10,11,17,20,20,
IIC 9 7 12,15,17,19,19,22,34 1 7 1 16
IIIB 1 1 8
IIIC 2 2 8,22
IVA L1 1 1 15
IVA L2 3 2 15,17 1 12
IVC L1 5 5 8,20,20,34,35
IVC L2 1 1 15
IVC L3 2 1 9 1 38
(B) Testicular seminoma
IIA 1 1 11
IIC 5 5 9,15,17,17,22
IVO Li 1 1 12
IVO L1
NED =No evidence of disease.
A+D=Alive with disease.
DID =Dead of intercurrent disease.
T=Time between start of chemotherapy and death (months).
DT=Dead of tumour.CHEMOTHERAPY OF GERM-CELL TESTICULAR TUMOURS 615
Histology
A histological diagnosis of germ-cell malignancy
was verified in all cases and classified as follows:
Malignant teratoma undifferentiated (MTU)
(embryonal carcinoma)
Malignant teratoma intermediate (MTI)
(teratocarcinoma)
Malignant teratoma trophoblastic (MTT)
Teratoma differentiated (TD)
Yolk sac carcinoma (YS)
Associated seminoma components were noted but
did not modify the classification. Seminoma
associated with a raised serum aFP level (serum AFP)
was regarded as a non-seminomatous germ-cell
tumour.
Treatment
Bleomycin and cis-platin were administered i.v. as
follows; bleomycin 30mg, Days 2, 9 and 16, and cis-
platin 20mgm-2 infused in one litre of normal
saline over 6h on each of Days 1-5. I.v. hydration
was started 12h prior to the first dose of cis-platin
and maintained throughout each cycle with normal
saline (11) and KCI (2 g F) infused 6 hourly for 5
days and 200mg of mannitol (10%) injected i.v.
daily prior to the start of the cis-platin infusion. In
the early phase of the study etoposide 120mgm-2
was given i.v. on Days 1-5. It was found necessary
to reduce the etoposide dose because of
haematological toxicity to etoposide 120mgm-2
Days 1-3. Cycles were given every 3 weeks unless
delayed by low blood counts for one week.
Renal clearance was measured initially and before
each cycle of chemotherapy. Full blood counts were
carried out prior to each course of chemotherapy,
twice weekly during the first week and on Days 9
and 16. Blood urea and electrolytes were checked
twice during the first week and plasma creatinine
measured weekly.
If complete remission had been achieved no
further treatment was given. If serum aFP and
jHCG levels were normal but residual masses were
present patients either proceeded to radiotherapy
(policy discontinued 1981), surgery or both, or to
further chemotherapy before local treatment
methods were considered. The rationale and
application of combined modality treatment is
discussed in detail elsewhere (Peckham, 1981b).
Of the 43 patients, 9 received 6 cycles of BEP,
one patient 5 cycles, one patient 3 cycles of BEP
and 3 of EP, 31 four cycles and one patient 2
cycles. Ten patients had elective radiotherapy after
chemotherapy and 11 patients came to surgery.
Results
The outcome of treatment of the whole group of 43
patients is shown in Tables II and III. Of the total
group 40 (93%) are alive and 37 (86%) free of
disease. Two patients died of uncontrolled
malignancy and one patient who had had prior
irradiation died of bronchopneumonia complicating
bleomycin lung damage. Of 36 testicular non-
seminoma patients 30 (83.3%) are alive and disease-
free. Table IV shows the outcome of treatment for
testicular non-seminoma patients in relation to the
volume of metastases. Twenty-two of 24 patients
with small volume disease and 15/19 with large
volume disease are alive and disease-free at 8-38
months after the start of chemotherapy. Table V
shows the results of treatment for non-seminoma
patients in relation to tumour volume and whether
or not they had received prior radiotherapy. Only
one relapse occurred in patients achieving complete
remission. This occurred one month after
Table III Bleomycin, etoposide and cis-platin (BEP) chemotherapy for
metastatic germ-cell tumours (The Royal Marsden Hospital 1979-1981)
Dead
Number of NED A+D DID
Tumour type patients (%) (%) DT(%) (%)
Seminoma testis 7 7 (100)
Non-seminoma
testis 36 30 (83.3) 3 (8.3) 2 (5.5) 1 (2.7)
Total 43* 37 (86%) 3 (6.9%) 2 (4.6%) 1 (2.3%)
For abbreviations see footnote to Table II.
*Observation time since start of chemotherapy 8-38 months (median 17
months).616 M.J. PECKHAM et al.
Table IV Bleomycin, etoposide and cis-platin for metastatic non-
seminomatous germ-cell testicular tumours: treatment results in
relation to tumour volume (The Royal Marsden Hospital 1979-
1981)
Alive
Patient subgroup No. ofpatients NED (%)
Small volume metastases 24 22 (91.7)
Bulky metastases 19 15 (78.9)
NED=no evidence of disease.
Table V Bleomycin, etoposide and cis-platin (BEP) for metastatic testicular non-seminoma:
treatment results in relation to tumour volume and previous therapy (The Royal Marsden Hospital
1979-1981)
Prior Stage No. NED* A+D DID DT
irradiation grouping ofpatients (%) (%) (%) (%)
SV° 14 13 (93) 1 (7)
No LV 14 12 (86) 1 (7) 1 (7)
Total in no prior
irradiation group 28 25 (89.3) 2 (7.1) 1 (3.6)
SV 3 2 1
Yes LV 5 3 1 1
Total in prior
irradiation group 8 5 (62.5) 1 (12.5) 1 (12.5) 1 (12.5)
*For abbreviations see footnote to Table II.
"SV =Small volume.
LV =Large volume.
See text for details.
completion of 6 cycles of BEP. Both patients dying
of tumour had uncontrolled disease with positive
histology in resected abdominal masses remaining
after chemotherapy and 3 patients who are alive
with disease failed to achieve complete remission.
Twenty-five of 28 (89.3%) previously untreated
patients are currently disease-free compared with
5/8 previously irradiated patients. There were no
differences in treatment outcome in relation to
histological subtype (Table VI). Table VII shows
treatment results in testicular non-seminoma
patients in relation to amount of etoposide
administered per cycle of chemotherapy.
Surgery
Of the 36 testicular non-seminoma patients 11
underwent post-chemotherapy surgery. One patient
had fibrotic tissue, 5 patients showed differentiated
teratoma and 5 histological evidence of residual
malignant teratoma. Of the 5 patients with residual
malignant tissue 2 subsequently died of their disease
and 2 are alive with disease at 15 and 38 months
and one is alive and disease-free at 12 months. The
5 patients with differentiated teratoma are alive at
9, 17, 18, 18 and 35 months. The patient with
fibrotic tissue only is alive and disease-free at 13
months.
Post chemotherapy irradiation
As described elsewhere (Peckham, 1981b) between
1976 and 1981 selected patients with testicular non-
seminoma received involved field irradiation after
chemotherapy. In the present series 10 patients were
managed in this way and all are alive and free from
disease at 15-22 months. None of this group came
to surgery. Six of 7 patients with seminoma (all with
abdominal node disease) had involved field
radiotherapy after chemotherapy.
Toxicity
The reported side effects of cis-platin include nauseaTable VI Bleomycin, etoposide and cis-platin (BEP)
chemotherapy for metastatic testicular germ-cell tumours: results
in relation to histology (The Royal Marsden Hospital 1979-1981)
No. of
Hi.stology patients NED* A+D DT DID
Seminoma 7 7
MTU 14 12 1 1
MTI 17 14 3
MTT 3 3
Sem AFP+ I I
Yolk Sac I I
Total 43 37 3 2 1
*For abbreviations see footnote to Table II.
Table VIl Bleomycin, etoposlide and cis-platin (BEP) for metastatic non-
seminomatous germ-cell testicular tumours: results in relation to dose of
etoposide per cycle ofchemotherapy (The Royal Marsden Hospital 1979-1981)
No prior radiotherapy Prior radiotherapy
No. ofdays of
etoposide per cycle 3 5 3 5
Total patients 16 12 1 7
Alive NED* 14 11 1 4
A+D 2 1
DT I I
DID I
*For abbreviations see footnote to Table II.
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and vomiting, nephrotoxicity, epilation, VIIIth
nerve damage and peripheral neuropathy.
Bleomycin administration may be associated with
chills, fever, cutaneous pigmentation, finger soreness
and swelling and lung damage. The major dose
limiting toxicity of etoposide is leukopenia and
thrombocytopenia is less frequent. Nausea and
vomiting, reversible alopecia, fever and chills,
hypotension and bronchospasm have also been
reported (Issell & Crooke, 1979). As shown in Table
VIII, haematological toxicity was mild and
unassociated with major infective episodes after
cycles of BEP containing 3 days of etoposide.
Toxicity was more severe after S day etoposide
cycles; 4 patients required hospitalisation for
neutropenic fever and were treated with broad
spectrum antibiotics and a 5th patient had proven
septicaemia. In addition, 4 patients developed chest
infections requiring admission to hospital and one
died. One patient developed a lung abcess and
another cellulitis. In the previously untreated group
the percentage of patients receiving cycles with 3
and S days of etoposide respectively who developed
low blood counts was as follows, white count
< 1.500 x 103: 3.8% vs 14.5%, platelets
< I100,000mm-3: 0% vs 11.3%.
Toxicity was more severe in previously irradiated
patients, although there are too few cycles with 3
days of etoposide to allow useful comparison. The
percentages of S day etoposide cycles followed by
low blood counts in irradiated (38 cycles) and non-
irradiated patients (62 cycles) were respectively:
white count <1500mm-3, 21% and 14%; platelets
< I100,000mm-3, 26.3% and 11.2%; haemoglobin
<IOgI-',28.9%and 12.9%.
No death occurred in previously untreated
patients, although one patient who had had prior
irradiation died of a fulminating chest infection
complicating bleomycin lung damage.
Epilation was invariable. Nausea and vomiting
varied in intensity and duration between patients
and from one cycle to another in individual
patients. Severe vomiting in one patient was
associated with haematemesis. All patients lost
weight during treatment and rapid weight gain
often with a tendency to exceed pre-treatment
weight was a common feature. Numbness,
thickening or tenderness of fingers and toes618 M.J. PECKHAM et al.
Table VIII Bleomycin, etoposide and cis-platin (BEP) for metastatic germ-cell tumours: toxicity in relation to etoposide dose per
cycle ofchemotherapy (The Royal Marsden Hospital 1979-1981)
Nadir blood count values
Number of White count Platelets Major infections
Prior Days of Total no. cycles delayed (x 103mm-3) mm-3 Haemoglobin requiring
radiotherapy etoposide ofcycles by one week <2.5 <1.5 <100,000 <50,000 <lOgm1- hospitalisation
3 10 (2) 8 (2) 8 2 1
Yes 5 38 (7) 26 (7) 30 8 10 2 11 Chest (3)
Lung abscess (1)
Septicaemia (11)
Bilat. pneumonia (1)
+Bleo pneumonitis
(died)
3 80 (19) 26 (10) 34 3 9 -
No 5 62 (15) 23 (9) 31 9 7 2 8 Cellulitis (1)
*Septicaemia (4)
Number in brackets indicates number ofpatients.
* =One positive blood culture.
occurred in 17 patients and was persistent and
troublesome in 6. Nine patients gave a history of
episodic finger or toe blanching (Raynaud's
phenomenon). In 2 patients this came on during
chemotherapy and in 7 from 1-5 months after
treatment. Symptomatic bleomycin lung toxicity
occurred in 2 patients. Both had received 540mg of
the drug. One patient spontaneously improved and,
as discussed above, the second died of a chest
infection. In the previously untreated group of
patients, 7/34 showed a >20% reduction in renal
clearance value compared with 4/9 in the previously
irradllttd group.
Discussion
The clinical experience summarised in this report
shows that BEP is a highly active combination with
25/28 (89.3%) of previously untreated testicular non-
seminoma patients alive and disease-free. Since
patients who are disease-free one year after starting
chemotherapy very rarely relapse (none in the
present series) it is probable that these data reflect
the cure potential of BEP although larger patient
numbers and longer observation times will be
necessary to establish this with confidence. No
formal comparison with PVB has been undertaken
but BEP would appear at least as active; indeed it
is encouraging that 15/19 previously untreated
testicular non-seminoma patients with bulky
metastases are disease-free.
BEP was developed initially to manage patients
relapsing after radiotherapy where PVB is extremely
hazardous and "analogous to remission induction
in acute myeloblastic leukaemia" (Einhorn &
Williams, 1980). Although the toxicity of BEP in
irradiated patients is more severe than in untreated
patients, in our experience the complications are
considerably less than those encountered after PVB.
In the initial PVB combination in which vinblastine
was used in a dose of 0.4mgkg-1 per cycle,
neutropenia was severe, 35% of patients developed
granulocytopenic fever and 12% proven septicaemia
(Einhorn & Donohue, 1977; Einhorn & Williams,
1980). A dose reduction of vinblastine to
0.3mgkg-1 was associated with less
myelosuppression without loss of therapeutic effect.
Even so, most patients experienced granulocyte
counts of <I000cu -mm and 15% were treated for
granulocytopenic fever (Einhorn & Williams, 1980).
In the present series the incidence of proven or
presumed septicaemia was 11.6% (5/43 patients).
The data with BEP containing three days of
etoposide indicate that as expected this is less
myelosuppressive than BEP with 5 days of
etoposide. Although a formal comparison of the
toxicity of PVB with 0.3mgkg-' vinblastine and
BEP with etoposide days 1-3 has not been
completed, we have little doubt having used both
regimens that the latter combination is better
tolerated both subjectively and objectively.
Obviously an important question is whether a dose
reduction of etoposide from 120mgm 2 x 5 to
120mgm-2 x 3 with each cycle is associated with
a reduction of anti-tumour activity. The present
data provide evidence that this is not the case
(Table VII). In the non-seminoma group of
previously untreated patients 16 received cycles
containing 3 days of etoposide and 12 patientsCHEMOTHERAPY OF GERM-CELL TESTICULAR TUMOURS 619
cycles containing 5 days of etoposide. The disease-
free survival rates are 14/16 (87.5%) and 11/12
(91.7%) respectively.
In current protocols all patients, except those
with small volume disease (Stages IM, IIA, IIB,
IIIA, IIIB, IVALj), are being treated with BEP to
obtain more information on the response of high
risk patients with bulky abdominal and
intrathoracic disease. Following the introduction of
BEP as first line chemotherapy for previously
unirradiated patients all patients were treated with
this combination. The only exclusions being 10 men
with advanced bulky presentations (IV L3 H+)
who were entered into a multicentre study of
bleomycin, etoposide, vinblastine and cis-platin
(BEVIP). Patients with small volume disease are
being entered into a Phase II study of etoposide
and cis-platin (EP) initiated in January 1982.
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